🇺🇸 SECGSK plcQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 00:26:23·⟳ 抓取 00:26:46 +23s·⚡ 决策 09-02 00:27:50 +1m04s·56.0 天前
GSK plc 提交例行月度总投票权通知（2026年8月），纯行政备案无交易含义
该 6-K 为 FCA 披露规则要求的月度总股本/投票权例行通知，不含业绩、指引、订单、监管、并购或任何业务增量信息，属于纯行政备案，不构成任何交易催化。
📄 原文GSK plc↗ 原文
----- a9126s.htm ----- 6-K 1 a9126s.htm TOTAL VOTING RIGHTS a9126s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was…
不做 GSK plc（GSK.US）
纯行政性月度投票权通知（FCA DTR 5.6.1R），不含任何业务、财务或战略增量信息，无交易催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
GSK plc 于2026年9月1日向 SEC 提交 Form 6-K，内容仅为按英国 FCA DTR 5.6.1R 规则披露截至2026年8月31日的已发行股本（43.16亿股）和总投票权（40.45亿），是每月固定的行政性合规披露。不含任何财务数据、业务进展、管理层变动或战略信息，对股价无影响，无交易价值。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例即可判定无交易价值
方向:无先例适用——纯行政备案不存在可比事件
涨幅量级:不适用
形态:不适用
原文全文
展开原文 · 2,135 字
----- a9126s.htm -----
6-K
1
a9126s.htm
TOTAL VOTING RIGHTS
a9126s
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 1 September 2026, London UK
Total Voting Rights
In conformity with the Financial Conduct Authority's
Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the
'Company') hereby notifies the market of the
following:
The Company's issued share capital as at 31 August 2026
consisted of 4,316,302,379 shares of 31 ¼ pence each
('Ordinary Shares'), of which 270,881,064 Ordinary Shares
were held in Treasury.
Therefore, the total number of voting rights in the Company
is 4,045,421,315. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency
Rules.
Notifications may be sent to
company.secretary@gsk.com
.
V A Whyte
Company Secretary
1 September 2026
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: September
01, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
6-K
1
a9126s.htm
TOTAL VOTING RIGHTS
a9126s
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 1 September 2026, London UK
Total Voting Rights
In conformity with the Financial Conduct Authority's
Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the
'Company') hereby notifies the market of the
following:
The Company's issued share capital as at 31 August 2026
consisted of 4,316,302,379 shares of 31 ¼ pence each
('Ordinary Shares'), of which 270,881,064 Ordinary Shares
were held in Treasury.
Therefore, the total number of voting rights in the Company
is 4,045,421,315. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency
Rules.
Notifications may be sent to
company.secretary@gsk.com
.
V A Whyte
Company Secretary
1 September 2026
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: September
01, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。